Disclosed is a pharmaceutical composition consisting of a monolithic core layer and a nonporous outer non-core layer, (A) wherein the core layer comprises a mixture of: (a) at least one opioid such as hydrocodone and (b) at least one (meth)acrylate polymer and at least one cellulose derivative (B) wherein the non-core layer consists of a non-opioid analgesic, a polyvinyl alcohol-polyethylene glycol-graft polymer, and colloidal silica (C) wherein the composition is adapted so as to be useful for oral administration to a human 3,2, or 1 times daily (D) wherein the core layer is manufactured by melt-extrusion followed by direct shaping of the drug-containing melt (E) wherein the active ingredients in the core layer are in a solid solution formed by the polymers of (b) and (F) wherein the non-core layer is applied to the core layer as an aqueous solution or suspension with a total solid content of at least 20percent by weight and an active ingredient content of at least 50 percent.
